Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 18;14(1):183.
doi: 10.1038/s41408-024-01168-7.

Appraising ascorbic acid as a chemoprevention agent for acute myeloid leukaemia using Mendelian Randomisation

Sina A Beer  1 , Molly Went  2 , Jessica M Hislop  2 , Richard Houlston  2 , Martin Kaiser  2   3
Affiliations

Appraising ascorbic acid as a chemoprevention agent for acute myeloid leukaemia using Mendelian Randomisation

Sina A Beer et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Mendelian randomisation (MR) study design and result summary.
MR has three key prerequisites for using single nucleotide polymorphisms (SNPs) as instrumental variables (IV): (1) The IVs must be independent of any confounders, (2) the IVs must be associated with the exposure, (3) the IVs should influence the outcome only through the exposure. (Upper part of diagram) Illustration of the MR approach using SNPs associated with the exposure ascorbic acid (AA) and its influence on the development of clonal haematopoiesis of indeterminate potential (CHIP) or acute myeloid leukaemia (AML). (Lower part of diagram) Depicts a Two-Sample MR (2SMR) analysis, where summary statistics from large genome wide association studies (GWAS) datasets were used to investigate a causal relationship between AA and CHIP/AML. No significant association was found. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Jani CT, Ahmed A, Singh H, Mouchati C, Al Omari O, Bhatt PS, et al. Burden of AML, 1990–2019: estimates from the global burden of disease study. JCO Glob Oncol. 2023;9:e2300229. - PMC - PubMed
    1. Brown KF, Rumgay H, Dunlop C, Ryan M, Quartly F, Cox A, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018;118:1130–41. - PMC - PubMed
    1. Kaweme NM, Zhou S, Changwe GJ, Zhou F. The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications. Biomark Res. 2020;8:63. - PMC - PubMed
    1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl J Med. 2016;374:2209–21. - PMC - PubMed
    1. Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170:1079–95.e20. - PMC - PubMed

LinkOut - more resources